Down 40%, Still Strong: Is Pro Medicus the Buy of the Decade?

Pro Medicus Ltd: A Rollercoaster Ride for Investors

Pro Medicus Ltd (ASX: PME) has experienced a tumultuous journey over the past few years. As a healthcare imaging software company, it has consistently showcased impressive margins, secured contracts with prestigious US hospitals, and maintained a share price that has resisted market downturns. However, this narrative has shifted significantly since the start of the year.

After reaching a peak above $230 earlier in the year, Pro Medicus shares have seen a decline of approximately 40%, even after a recent recovery. This drop has sparked a critical question among investors: Is this the long-awaited buying opportunity for long-term shareholders?

The Bull Case for Pro Medicus

Despite the sharp correction in its share price, Pro Medicus’ business operations continue to perform exceptionally well. In its HY26 results, the company reported a revenue increase of 28.4% to $124.8 million, with underlying profit before tax rising nearly 30%. More impressively, EBIT margins expanded to an extraordinary 73%.

Importantly, Pro Medicus is debt-free and holds more than $220 million in cash and financial assets. On the operational front, its flagship Visage imaging platform continues to gain traction across major US healthcare systems. Recently, Pro Medicus has announced multiple significant contract wins and renewals, including a $37 million extension with Northwestern Medicine.

This growth is particularly encouraging due to the stickiness of Pro Medicus’ contracts. Its software is deeply embedded into hospital imaging workflows, making these systems difficult to replace and creating strong switching costs and recurring revenue streams.

Potential Risks to Consider

Of course, there are still risks associated with investing in Pro Medicus. Even after the recent sell-off, the company remains quite expensive when viewed through traditional valuation metrics. This means volatility could persist, and management has limited room for earnings disappointments.

Quality businesses rarely become genuinely “cheap.” Instead, the market may offer investors the chance to buy elite companies at more attractive entry points. Another factor to consider is AI disruption. However, given the specialized nature of Pro Medicus’ software and its critical role within hospital operating systems, it is unlikely that AI will replace its product offering.

Analysts like Bell Potter seem to align more with the bull case for Pro Medicus, reiterating its buy rating and maintaining a $240 price target following the earnings report.

Foolish Takeaway

If management continues to execute effectively, the current pullback may present an attractive entry point for some investors. With strong fundamentals and a sticky revenue base, Pro Medicus is well-positioned to deliver value into the future.

For investors with a long-term horizon, this stock is starting to look interesting again.

Additional Information

Before purchasing Pro Medicus shares, potential investors should consider various factors. Motley Fool investing expert Scott Phillips recently highlighted what he believes are the five best stocks for investors to buy right now, and Pro Medicus was not among them.

The online investing service he has run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have seen significant returns. Currently, Scott believes there are five stocks that may be better buys.

For those interested in exploring these opportunities, further details can be found by clicking on the link provided.